JANSSEN DURAGESIC FENTANYL TRANSDERMAL PATCH APPROVED FOR CHRONIC PAIN, ONE WEEK AFTER NDA DAY; J&J R&D PARTNER ALZA WILL CO-PROMOTE TO ONCOLOGISTS